GlassScriptPhysician profile
Jeffrey A Rebman
NPI 1053315077
$1,890.69
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $214 · 2021: $414 · 2022: $387 · 2023: $315 · 2024: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $451.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $523.33 | 2019-2024 | Myrbetriq |
| Myriad Genetic Laboratories, INC. | $158.40 | 2021-2023 | Prolaris |
| Bayer Healthcare Pharmaceuticals INC. | $147.92 | 2021-2023 | |
| Dornier Medtech America, INC | $134.80 | 2023 | Dornier Medtech |
| Myovant Sciences INC. | $105.15 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $97.44 | 2019-2022 | |
| Allergan, INC. | $85.50 | 2019-2020 | |
| Blue Earth Diagnostics | $83.68 | 2019-2023 | |
| Teleflex LLC | $62.95 | 2021-2022 | |
| Antares Pharma, INC. | $58.50 | 2022 | |
| Accord Healthcare, INC. | $54.84 | 2024 | |
| Laborie Medical Technologies Corp. | $53.29 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Clarus Therapeutics INC. | $47.16 | 2021 | |
| Neotract INC. | $33.40 | 2019-2020 | |
| Tolmar Pharmaceuticals, INC. | $30.82 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 180 Medical, INC. | $29.65 | 2019 | |
| Progenics Pharmaceuticals, INC. | $28.05 | 2023-2024 | Pylarify |
| Abbvie INC. | $24.17 | 2019 | |
| Halozyme INC | $23.31 | 2023 | |
| Sumitomo Pharma America, INC. | $23.02 | 2023 | Orgovyx |
| Rochester Medical Corporation | $22.70 | 2022 | |
| Metuchen Pharmaceuticals | $19.11 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.19 | 2019 | |
| Pfizer INC. | $15.09 | 2020 | |
| Mission Pharmacal Company | $13.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Rebman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.